Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
Recent advances in the treatment and management of haematological malignancies are due in large part to an improved understanding of the basic biology that drives tumour cell growth and survival. This improved understanding has led to the clinical study and approval of a number of different targeted agents across a number of different haematological tumours. This review of clinical data covers some of the exciting clinical advances that were reported at the recent American Society of Hematology meeting in San Diego, USA. This paper focuses on three important areas of biological research that has yielded clinical trials that have affected clinical outcomes. The areas covered include proteasome inhibition and myeloma, tyrosine kinase inhibitors that are directed at the BCR-ABL fusion protein and chronic myeloid leukaemia/acute lymphoblastic leukaemia, and FLT3 inhibitors and acute myeloid leukaemia acute lymphoblastic leukaemia therapy.
Haas
Maureen
M
Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Lonial
Sagar
S
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006405:Hematology / Q000379:methods / Q000639:trends*; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D012955:Societies, Medical; D014481:United States
D000970:Antineoplastic Agents